GoodRx (NASDAQ:GDRX – Get Rating) had its price target dropped by equities researchers at Barclays from $9.00 to $8.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 54.44% from the company’s previous close.
Several other equities research analysts also recently issued reports on the company. The Goldman Sachs Group decreased their price target on GoodRx from $10.00 to $8.00 and set a “neutral” rating for the company in a report on Wednesday, November 9th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of GoodRx from $9.00 to $7.00 in a report on Thursday, November 10th. Citigroup initiated coverage on shares of GoodRx in a report on Thursday, December 1st. They set a “buy” rating and a $7.00 price target on the stock. DA Davidson decreased their price objective on shares of GoodRx to $5.00 in a research note on Tuesday, November 15th. Finally, JPMorgan Chase & Co. upgraded GoodRx from an “underweight” rating to a “neutral” rating and cut their target price for the stock from $10.00 to $8.00 in a research note on Friday, November 4th. Fifteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, GoodRx currently has an average rating of “Hold” and an average target price of $9.45.
GoodRx Trading Down 0.6 %
GDRX opened at $5.18 on Wednesday. GoodRx has a fifty-two week low of $3.82 and a fifty-two week high of $30.89. The firm has a market capitalization of $2.05 billion, a PE ratio of -30.47, a P/E/G ratio of 13.57 and a beta of 0.71. The company has a debt-to-equity ratio of 0.83, a current ratio of 10.34 and a quick ratio of 10.34. The company’s 50-day moving average is $4.94 and its 200 day moving average is $5.55.
Hedge Funds Weigh In On GoodRx
GoodRx Company Profile
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
- Get a free copy of the StockNews.com research report on GoodRx (GDRX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.